Drug-Eluting Stent Implantation May Not Affect Vasomotor Function in Early Phase  by Nakazawa, Gaku et al.
*Nico H. J. Pijls, MD, PhD
Pepijn van Schaardenburg, MD
Ganesh Manoharan, MD
Erik Boersma, PhD
Jan-Willem Bech, MD, PhD
Marcel van’t Veer, MSc
Frits Bär, MD, PhD
Jan Hoorntje, MD, PhD
Jacques Koolen, MD, PhD
William Wijns, MD, PhD
Bernard de Bruyne, MD, PhD
*Catharina Hospital
Cardiology
Michelangelolaan 2
P.O. Box 1350
5602-ZA Eindhoven
Noord-Brabant 5602
the Netherlands
E-mail: carias@cze.nl
doi:10.1016/j.jacc.2007.11.057
REFERENCES
1. Pijls NHJ, van Schaardenburgh P, Manoharan G, et al. Percutaneous
coronary intervention of functionally nonsignificant stenosis: 5-year
follow-up of the DEFER study. J Am Coll Cardiol 2007;49:2105–11.
2. Boden WE, O’Rourke RA, Teo KK, et al., COURAGE Trial Research
Group. Optimal medical therapy with or without PCI for stable coronary
disease. N Engl J Med 2007;12:1503–16.
3. Botman KJ, Pijls NHJ, Bech GJW, et al. Percutaneous coronary interven-
tion or bypass surgery in multivessel coronary disease? A tailored approach
based on coronary pressure measurement. Cathet Cardiovasc Interv 2004;
63:184–91.
4. Sant’Anna FM, Silva EE, Batista LA, et al. Influence of routine assessment
of fractional flow reserve on decision making during coronary interventions.
Am J Cardiol 2007;99:504–8.
5. Thygesen K, Alpert JS, White HD. Universal definition of myocardial
infarction. Eur Heart J 2007;28:2525–38.
Drug-Eluting Stent
Implantation May
Not Affect Vasomotor
Function in Early Phase
The study by Obata et al. (1) demonstrates that drug-eluting stents
(DES) adversely affect endothelium-dependent vasomotor function
with a reduction in vascular endothelial growth factor (VEGF). This
report addressed a very important issue because it has been reported
that endothelialization and its function are impaired following
DES implantation (2,3). However, we are not convinced by the
findings in the present study that DES affect vasomotor function
2 weeks after implantation. As we have previously reported (4),
there is no histologic difference between DES and bare-metal
stents (BMS) within 2 weeks following implantation. Moreover,
vascular healing of the stented segment in acute myocardial
infarction generally takes a much longer time to complete than
stable plaques do in the case of both DES and BMS because these
lesions generally contain large necrotic cores. Therefore, it is
surprising that the authors report differences in response to
intracoronary acetylcholine because the extent and functionality of
endothelium for lesions stented with either DES or BMS lesions
is not different 2 weeks after implantation. Furthermore, angiog-
raphy cannot detect the underlying atherosclerotic disease in the
distal segments where vasomotor function was assessed, and it is
possible that the differences observed were due to differences in
atherosclerotic burden between the 2 groups because endothelial
function has been shown to be heavily influenced by the presence
of underlying atherosclerotic disease.
The authors also speculate that lack of VEGF in DES might be
responsible for impaired endothelialization or its function. As the
authors mentioned in the introduction, a compensatory up-regulation
of VEGF is usually observed when endothelium is denuded, whereas
VEGF is down-regulated upon complete re-endothelialization (5).
We do agree that high blood concentrations of sirolimus at an early
time point could impair endothelial cells in the portion distal to the
stent and be responsible for vasomotor dysfunction. However, the
sirolimus concentration in the anterior interventricular vein is far
below its IC50 (1.0 to 1.5 nmol/l) even at 3 days (0.5 nmol/l) and
even further below at 2 weeks (0.2 nmol/l) following implantation.
Even if sirolimus had a detrimental effect on endothelial cells in
the distal vessel, the VEGF level should be higher in the presence
of active ongoing arterial repair. In fact, our in vitro and in vivo
data clearly showed VEGF up-regulation after endothelial injury.
In our own assays, human umbilical vein endothelial cells are grown
until confluence and VEGF expression is measured using Cytokine
Array (RayBiotech Inc., Norcross, Georgia) in the presence and
absence of scratching or treatment with everolimus (2 nmol/l) for
16 h. The VEGF was greater in the scratched and everolimus group
(1.7  0.4- and 1.8  0.6-fold increase, respectively) as compared
with the nonscratched control group. Similarly, we have observed
up-regulation of VEGF messenger ribonucleic acid in the bare-metal
stented rabbit iliac arteries as compared with nonstented iliac arteries
at 7 days (1.4  0.2-fold-increase). Thus, VEGF is up-regulated in
the lesions where endothelialization is incomplete. It is hard to
reconcile these findings with those of Obata et al. (1). The vascular
biology of DES implantation is just being understood and larger
clinical studies as well as preclinical studies are needed to deepen
our understanding.
Gaku Nakazawa, MD
Qi Cheng, MD
Xin Xu, PhD
Aloke V. Finn, MD
Frank D. Kolodgie, PhD
*Renu Virmani, MD
*CVPath Institute Inc
19 Firstfield Road
Gaithersburg, Maryland 20878
E-mail: rvirmani@cvpath.org
doi:10.1016/j.jacc.2007.11.055
Please note: Dr. Virmani receives research support from Medtronic AVE, Abbott
Vascular, Conor Medsystems, OrbusNeich, Terumo Corporation, Cordis Corpora-
tion, BioSensors International, Prescient Medical, Biotronik, and Alchimedics. She
consults for Medtronic AVE, Abbott Vascular, Prescient Medical, and Biotronik.
REFERENCES
1. Obata JE, Kitta Y, Takano H, et al. Sirolimus-eluting stent implanta-
tion aggravates endothelial vasomotor dysfunction in the infarct-related
1124 Correspondence JACC Vol. 51, No. 11, 2008
March 18, 2008:1123–6
coronary artery in patients with acute myocardial infarction. J Am Coll
Cardiol 2007;50:1305–9.
2. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in
humans: delayed healing and late thrombotic risk. J Am Coll Cardiol
2006;48:193–202.
3. Togni M, Windecker S, Cocchia R, et al. Sirolimus-eluting stents
associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol
2005;46:231–6.
4. Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug
eluting stents: importance of delayed healing. Arterioscler Thromb Vasc
Biol 2007;27:1500–10.
5. Wysocki SJ, Zheng MH, Smith A, Norman PE. Vascular endothelial
growth factor (VEGF) expression during arterial repair in the pig. Eur
J Vasc Endovasc Surg 1998;15:225–30.
Reply
We appreciate the opportunity to reply to questions raised by Dr.
Nakazawa and colleagues. Please note that the coronary arteries
distal to the stented segment but not the stented lesion were
examined for the endothelial vasomotor function in our study (1).
As described in our study (1), myocardial ischemia-reperfusion
induces endothelial injury in the coronary trees for their entirety
distal to the occluded segment in the infarct-related coronary
artery. Thus, the healing process of the coronary arteries distal to
the stented segment but not the stented lesion affected our data.
Our previous reports (2–5) agreed that the atherosclerotic burden
strongly affects coronary endothelial vasomotor functions. How-
ever, our study (1) showed that the frequencies of the atheroscle-
rotic risk factors were comparable between the drug-eluting stent
(DES) and bare-metal stent (BMS) groups. In addition, the 2
groups had no difference in cardiac medications, lesion, and
procedural variables of percutaneous coronary intervention except
for stent selection, and acute myocardial infarction (AMI)–related
variables that potentially influence the coronary endothelial vaso-
motor function, as described in our study (1). Thus, the implanted
stents were only the discriminate factor for the difference in the
coronary endothelial vasomotor responses to acetylcholine between
the patients treated with BMS and DES.
A number of previous reports (6,7) demonstrated that the
vascular endothelial growth factor (VEGF) expression is increased
in cardiomyocytes as well as vascular endothelial cells in ischemic
or injured hearts and that sirolimus is capable of inhibiting VEGF
production and the VEGF-mediated cellular signaling pathway in
various types of cells. Our study (1) also showed that VEGF levels
in the anterior interventricular vein (AIV), reflecting VEGF levels
released from the ischemic myocardium, were increased in AMI
patients treated with BMS compared with control subjects. As we
described in our study (1), sirolimus levels in AIV in our study
were 10- to 500-fold lower than the levels to exert its biological
effects in vitro experiments (8,9). Considering the fact that
sirolimus is eluted into coronary circulation over a period of 4
weeks, these exposure times were much longer as compared with
the in vitro experiments. Moreover, the chronic exposure to the
circulating sirolimus might cause a local accumulation of consid-
erable amounts of this drug in the myocardium and the entire
vascular bed distal to sirolimus-eluting stent (SES) in the infarct-
related coronary artery. Thus, there is a possibility that SES could
induce a decrease in VEGF release from myocardium and endo-
thelium of large and resistance vessels, which may play a possible
role in the mechanisms for endothelial vasomotor dysfunction in
the infarct-related coronary arteries treated with SES.
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Early Detection of
Rheumatic Heart Disease
and Prevention of Heart
Failure in Sub-Saharan Africa
In a recent issue of the Journal, Damasceno et al. (1) highlighted
the need for action to reduce the prevalence of heart failure in
sub-Saharan Africa, where this pathology is an important cause of
mortality as well as a serious economic burden. Rheumatic heart
disease is the most frequent cause of heart failure in this region of
the world and is responsible for at least one-third of cases. In this
context, the authors are prudent to insist on the need for a strategy
of prevention with regards to risk factors for heart failure. Never-
theless, we would like to underline important new findings that
should be considered when attempting to reduce the incidence of
this life-threatening pathology.
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